Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagPEP: Magnesium Sulfate for Post-ERCP Pancreatitis
NCT03749590Phase 3Terminated
- Sponsor
- Universitätsklinikum Greifswald
- Start
- Aug 2012
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing Magnesium Sulfate with Placebo (2 arms). Primary endpoint: Reduction in the incidence of post-ERCP pancreatitis. Started Aug 2012; status: terminated.
02
Drugs
magnesium sulfate
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT03749590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749590.